Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
AC Immune SA ACIU
$2.11
-$0.01 (-0.24%)
На 18:00, 12 мая 2023
+373.93%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
175602840.00000000
-
week52high
3.90
-
week52low
1.68
-
Revenue
3935000
-
P/E TTM
-2
-
Beta
0.58685100
-
EPS
-0.87000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 июл 2023 г. в 12:30
Описание компании
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 11 июл 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 дек 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 24 мар 2021 г. |
| H.C. Wainwright | Buy | 10 дек 2019 г. | |
| UBS | Neutral | Buy | 01 февр 2019 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline
GlobeNewsWire
20 мар 2023 г. в 08:00
AC Immune at AD/PD ™ 202 3 to Present New Clinical and Preclinical Data f rom its Precision Medicine Pipeline
AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures
Seeking Alpha
18 мар 2023 г. в 09:00
ACIU is a leading researcher in the field of dementia, with major deals with big pharma. Unfortunately, AD is a tough space and none of its molecules have turned out well so far.
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
GlobeNewsWire
08 мар 2023 г. в 07:00
AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023
AC Immune to Present at the SVB Securities Global Biopharma Conference
GlobeNewsWire
02 февр 2023 г. в 08:15
AC Immune to Present at the SVB Securities Global Biopharma Conference
Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket
Seeking Alpha
27 дек 2022 г. в 13:02
ACIU has recently fallen due to what looks like indiscriminate tax loss selling. It now trades at near cash on hand and yet it has numerous programs in clinic and prestigious partners.